Rituximab, a lower-cost treatment, may be as effective at managing RRMS as the approved therapy Ocrevus, a new study from ...

Dr Pavan Bhargava gives insights on earlier diagnosis, ocrelizumab safety in pregnancy, and promising anti-aging effects of diet in RRMS.

The following is a summary of “Recall vaccination increases detectable B-cell reactivity in persons with multiple sclerosis treated with ocrelizumab,” published in the April 2025 issue of Journal of ...

One in three women diagnosed with MS will subsequently conceive, therefore consideration of the maternal-infant dyad is ...

The findings indicate that the currently approved 600-mg dose of intravenous ocrelizumab is optimal to significantly slow ...

That theory triumphed and led to the 2017 approval of ocrelizumab, the first in a new class of therapies for MS. “A few decades ago, young scientists were advised to pick another disease to study,” ...

That theory triumphed and led to the 2017 approval of ocrelizumab, the first in a new class of therapies for MS. “A few decades ago, young scientists were advised to pick another disease to study,” ...

In the Phase III MUSETTE study, a higher dose of intravenous Ocrevus (ocrelizumab) did not provide additional benefit in slowing disability progression compared to the currently approved 600mg dose.

Two prominent scientists who study multiple sclerosis — Dr. Alberto Ascherio and Dr. Stephen Hauser — are co-winners of a ...

Findings confirmed the approved 600mg IV dose was optimal for slowing disability progression in relapsing MS. A phase 3 study evaluating a higher dose of ocrelizumab in adults with relapsing ...

Swiss pharma giant Roche RHHBY faced a setback in its efforts to develop a higher dose of multiple sclerosis drug Ocrevus (ocrelizumab). The company announced that a phase III study, MUSETTE, which ...